FIA 586
Alternative Names: FIA-586Latest Information Update: 23 Aug 2022
At a glance
- Originator Novartis Pharmaceuticals
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jun 2022 Novartis complets a phase I pharmacokinetics trial in Non-alcoholic-steatohepatitis (in subjects with impaired and normal hepatic function) in USA (PO) (NCT04993157)
- 10 Dec 2021 Novartis initiates enrolment in a phase I pharmacokinetics trial in Non-alcoholic-steatohepatitis in subjects with impaired and normal hepatic function in USA (PO) (NCT04993157)
- 06 Aug 2021 Novartis Pharmaceuticals plans a phase I trial in Healthy volunteers (PO, Capsule), in August 2021 (NCT04993157)